OPK
OPKO Health, Inc.
OPK lost money over the past year, so it has no meaningful PE right now.
OPK Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Strong |
OPK's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
OPK PE Valuation
OPK has no meaningful PE right now: it lost money over the past year.
OPK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect OPK's revenue and profitability to decline, with its earnings holding steady. However, they disagree widely on these estimates.
OPK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.19 | +$0.06 |
| Q2 2026 | -$0.09 | +$0.16 |
| Q1 2026 | -$0.27 | -$0.20 |
| Q4 2025 | -$0.30 | -$0.21 |
| Q3 2025 | -$0.25 | -$0.06 |
| Q2 2025 | -$0.25 | +$0.08 |
| Q1 2025 | -$0.07 | +$0.28 |
| Q4 2024 | -$0.09 | +$0.16 |
OPK is still losing money, but far less than before: $0.19 per share over the past year, against $0.53 at its worst in late 2019.
OPK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $65.4M | -57% |
| Q2 2026 | $163.6M | +4.3% |
| Q1 2026 | $124.2M | -17% |
| Q4 2025 | $148.5M | -19% |
| Q3 2025 | $151.7M | -13% |
| Q2 2025 | $156.8M | -14% |
| Q1 2025 | $150M | -14% |
| Q4 2024 | $183.6M | +1% |
OPK's revenue has slid since its 2021 peak: $65M last quarter, down 57% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -48% | -80 points |
| Q2 2026 | -4.3% | +34 points |
| Q1 2026 | -41% | +3.7 points |
| Q4 2025 | -26% | -7.8 points |
| Q3 2025 | 32% | +24 points |
| Q2 2025 | -38% | -4.4 points |
| Q1 2025 | -45% | -3.6 points |
| Q4 2024 | -18% | +20 points |
OPK's operating margin was −48% last quarter, down 80 points from the same quarter a year ago, near the bottom of its range since 2019.
OPK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$39.1M | -$1.3M |
| Q2 2026 | -$46.5M | +$40.2M |
| Q1 2026 | -$21.1M | +$16.6M |
| Q2 2025 | -$86.7M | -$53.1M |
| Q1 2025 | -$37.7M | +$2.3M |
| Q2 2024 | -$33.7M | -$27.3M |
| Q1 2024 | -$40M | -$14.3M |
| Q4 2023 | -$41.3M | -$3.4M |
OPK has burned cash in most quarters: −$135M over the past year, against −$196M the year before.
OPK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -7.2x | Net Cash |
| Q4 2021 | 0.7x | Very low |
| Q3 2021 | -0.7x | Net Cash |
| Q2 2021 | -0.3x | Net Cash |
| Q1 2021 | -0.4x | Net Cash |
| Q4 2020 | 1.3x | Healthy |
OPK has more cash than debt.
OPK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.9 | Neutral |
| Stochastic | 74.7 | Neutral |
OPK's weekly RSI is 59 (neutral) and its Stochastic is 75 (neutral).
OPK PE vs Healthcare Sector
| Metric | OPK | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
OPK has no meaningful PE right now: it lost money over the past year.
OPK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.60 | 4.4% above |
| 20 week MA | $1.50 | 11% above |
| 50 week MA | $1.36 | 23% above |
| 100 week MA | $1.40 | 19% above |
| 200 week MA | $1.42 | 18% above |
OPK has climbed back above all five of its weekly moving averages, and it's now 18% above its 200-week average.
OPK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.50 | $4.23 | +182% |
| 2021 | $4.23 | $4.77 | +13% |
| 2022 | $4.77 | $1.14 | -76% |
| 2023 | $1.14 | $1.51 | +32% |
| 2024 | $1.51 | $1.48 | -2% |
| 2025 | $1.48 | $1.29 | -13% |
| 2026 YTD | $1.29 | $1.67 | +29% |
OPK's yearly returns have swung widely, from +182% in 2020 to −76% in 2022. It's up 29% so far in 2026.